Literature DB >> 35449628

An Atypical Presentation of a Severe Case of Anaplasma Phagocytophilum.

Sameer Kandhi1, Haider Ghazanfar1, Zaheer A Qureshi2,1, Harika Kalangi1, Abhilasha Jyala1, Esther S Arguello Perez3.   

Abstract

We report a case of a 79-year-old male presenting to a South Bronx hospital with complaints of fever, shortness of breath, severe thrombocytopenia, hematuria, elevated liver enzymes, and acute renal failure. The patient rapidly progressed to acute hypoxic respiratory failure requiring mechanical ventilation. Treatment was delayed for six days because the tick-borne disease was not considered in the differential. Empirical treatment of tick-borne illnesses should be considered in the proper clinical setting, and travel history should be relevant in any patient presenting with fever. Delay in appropriate treatment results in the onset of more severe illness.
Copyright © 2022, Kandhi et al.

Entities:  

Keywords:  anaplasma; anaplasmosis; black-legged ticks; elevated liver functions; infectious disease; leucopenia; thrombocytopenia; ticks

Year:  2022        PMID: 35449628      PMCID: PMC9012425          DOI: 10.7759/cureus.23224

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  10 in total

1.  Case 16-2018: A 45-Year-Old Man with Fever, Thrombocytopenia, and Elevated Aminotransferase Levels.

Authors:  Kimiyoshi J Kobayashi; Ana A Weil; John A Branda
Journal:  N Engl J Med       Date:  2018-05-24       Impact factor: 91.245

Review 2.  Human granulocytic anaplasmosis.

Authors:  Johan S Bakken; J Stephen Dumler
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

3.  Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila.

Authors:  J S Dumler; A F Barbet; C P Bekker; G A Dasch; G H Palmer; S C Ray; Y Rikihisa; F R Rurangirwa
Journal:  Int J Syst Evol Microbiol       Date:  2001-11       Impact factor: 2.747

4.  Lyme disease and human granulocytic anaplasmosis coinfection: impact of case definition on coinfection rates and illness severity.

Authors:  Harold W Horowitz; Maria E Aguero-Rosenfeld; Diane Holmgren; Donna McKenna; Ira Schwartz; Mary E Cox; Gary P Wormser
Journal:  Clin Infect Dis       Date:  2012-10-05       Impact factor: 9.079

Review 5.  Anaplasma and Ehrlichia infection.

Authors:  J Stephen Dumler
Journal:  Ann N Y Acad Sci       Date:  2005-12       Impact factor: 5.691

6.  Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States.

Authors:  Max Maurin; Johan S Bakken; J Stephen Dumler
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

7.  Clinical and laboratory characteristics of human granulocytic ehrlichiosis.

Authors:  J S Bakken; J Krueth; C Wilson-Nordskog; R L Tilden; K Asanovich; J S Dumler
Journal:  JAMA       Date:  1996-01-17       Impact factor: 56.272

8.  Co-infection of Ticks: The Rule Rather Than the Exception.

Authors:  Sara Moutailler; Claire Valiente Moro; Elise Vaumourin; Lorraine Michelet; Florence Hélène Tran; Elodie Devillers; Jean-François Cosson; Patrick Gasqui; Van Tran Van; Patrick Mavingui; Gwenaël Vourc'h; Muriel Vayssier-Taussat
Journal:  PLoS Negl Trop Dis       Date:  2016-03-17

9.  Severe Anaplasmosis presenting as possible CVA: Case report and 3-year Anaplasma infection diagnosis data is based on PCR testing and serology.

Authors:  Yasser Eldaour; Rahman Hariri; Mohamed Yassin
Journal:  IDCases       Date:  2021-03-10

Review 10.  Human granulocytic anaplasmosis and Anaplasma phagocytophilum.

Authors:  J Stephen Dumler; Kyoung-Seong Choi; Jose Carlos Garcia-Garcia; Nicole S Barat; Diana G Scorpio; Justin W Garyu; Dennis J Grab; Johan S Bakken
Journal:  Emerg Infect Dis       Date:  2005-12       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.